BridgeMD
Metal Panel Patch Test
EU CTIS ID: 2023-507972-35-00
What this study is testing
The objective of this study is to evaluate the diagnostic efficacy and safety of the investigational allergens and overall safety and performance of the investigational panel device constituent.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- a. 18 years of age or older
- b. Group 1: Active dermatitis that is suspected to be allergic contact dermatitis to one or more of the metal panel allergens or a recent history (within the past 5 years) of dermatitis that is suspected to be due to metal allergy, and that resolved prior to enrollment due to treatment or elimination of exposure to the suspected metal trigger. Population may include individuals with suspected allergic contact dermatitis due to a positive patch test within the preceding 10 years and/or a metal implant. Group 2: No history or symptoms of dermatitis related skin disease.
- c. Group 2 only: No past or current body piercings, dental appliances, braces, fillings, implants, prosthesis or restorations, surgical hardware, orthopedic implants or cardiac implants.
- d. Group 2 only: No routine occupational or long term exposure to metals
- e. Unable to become pregnant or willing to use an acceptable method of contraception to prevent pregnancy if female of childbearing potential
- f. Understands and signs the approved Informed Consent form which is consistent with all institutional, local and national regulations
You likely can't join if
- a. Participation in Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study, SP12 2PM2 201, or Clinical Evaluation of Metal Panel Allergens: Aluminum, Copper, Manganese, Molybdenum, Tin, Titanium, Vanadium and Zinc Dose Response Study, SP14 8MP 201.
- j. Inability to comply with patch test study requirements including multiple return visits and activity restrictions (e.g., protecting test panels from excess moisture due to showering or vigorous activity).
- k. Participation in a clinical trial of an investigational drug, treatment or device during this study or 3 weeks prior to inclusion in this study.
- l. An opinion of the Investigator that deems the potential subject to be non-compliant, unable to return for study visits or complete the study as detailed in the protocol.
- m. Alcohol abuse as well as drug and/or medication abuse. GERMANY ONLY
- n. Severe psychiatric, psychological or neurological disorders. GERMANY ONLY
See the full eligibility criteria
Who can join
- a. 18 years of age or older
- b. Group 1: Active dermatitis that is suspected to be allergic contact dermatitis to one or more of the metal panel allergens or a recent history (within the past 5 years) of dermatitis that is suspected to be due to metal allergy, and that resolved prior to enrollment due to treatment or elimination of exposure to the suspected metal trigger. Population may include individuals with suspected allergic contact dermatitis due to a positive patch test within the preceding 10 years and/or a metal implant. Group 2: No history or symptoms of dermatitis related skin disease.
- c. Group 2 only: No past or current body piercings, dental appliances, braces, fillings, implants, prosthesis or restorations, surgical hardware, orthopedic implants or cardiac implants.
- d. Group 2 only: No routine occupational or long term exposure to metals
- e. Unable to become pregnant or willing to use an acceptable method of contraception to prevent pregnancy if female of childbearing potential
- f. Understands and signs the approved Informed Consent form which is consistent with all institutional, local and national regulations
What rules you out
- a. Participation in Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study, SP12 2PM2 201, or Clinical Evaluation of Metal Panel Allergens: Aluminum, Copper, Manganese, Molybdenum, Tin, Titanium, Vanadium and Zinc Dose Response Study, SP14 8MP 201.
- j. Inability to comply with patch test study requirements including multiple return visits and activity restrictions (e.g., protecting test panels from excess moisture due to showering or vigorous activity).
- k. Participation in a clinical trial of an investigational drug, treatment or device during this study or 3 weeks prior to inclusion in this study.
- l. An opinion of the Investigator that deems the potential subject to be non-compliant, unable to return for study visits or complete the study as detailed in the protocol.
- m. Alcohol abuse as well as drug and/or medication abuse. GERMANY ONLY
- n. Severe psychiatric, psychological or neurological disorders. GERMANY ONLY
- o. Patients in any relationship or dependency with the sponsor and/or investigator. GERMNY ONLY
- p. General inflammatory as well severe acute and chronic inflammatory diseases. GERMANY ONLY
- q. Malignancy during the previous 5 years. GERMANY ONLY
- r. Completed or ongoing long-term treatment with tranquilizer or psycho active drug.
- b. Breastfeeding or pregnant (as determined by urine pregnancy test) or intending to become pregnant during the course of the study. Breastfeeding may be resumed upon completion of the study
- c. Topical treatment with corticosteroids or other immunosuppressive agents on or near the test area 14 days prior to inclusion through the end of the subject’s participation in the study.
- d. Systemic treatment with corticosteroids (equivalent to > 10 mg prednisone) or other immunosuppressive agents 14 days prior to inclusion through the end of the subject’s participation in the study. Inhaled treatments and steroidal nose or eye drops are permitted.
- e. Treatment with ultraviolet (UV) light (including tanning) during the 3 weeks prior to inclusion through the end of the subject’s participation in the study.
- f. Acute dermatitis outbreak or dermatitis on or near the test area on the back.
- g. Known or suspected infection of the skin, joints or other site(s) associated with metal exposure
- h. Condition such as, fibromyalgia, chronic fatigue, depression, cognitive impairment, flu-like symptoms, diarrhea and/or headache without at least one of the symptoms related to metal exposure listed in Section 6.6.
- i. Condition such as, psoriasis, dermatitis herpetiformis, mycosis fungoides or cutaneous T-cell lymphoma that may confound the evaluation of allergic contact dermatitis.
The study team makes the final eligibility decision.
Where it's taking place
- United States
- Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; Japan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.